![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, August 10, 2019 2:54:35 PM
I will tell you this: when you look at the current state of the universe, and see how the internet has connected us to allow us all to delve into the minutiae of everything you’ll find that sometimes that minutiae causes one to feel things are more complicated than they need to be.
I do believe the SAP is being done pretty much in the way you surmise. If you look, for example, at the Keytruda Study application to the EMA for a variation to include use for the treatment for head and neck Squamous Cell Carcinoma to the indications already approved for NSCLC it will make your head spin. In that application they noted that:
“Overall, the statistical analyses proposed in the protocol are considered adequate. However, the protocol was amended several times and the changes have HEAVILY MODIFIED THE STATISTICAL COMPONENT OF THE STUDY DESIGN (definition of primary endpoint, stratification factors, follow-up duration, unplanned crossover) and sample size, and therefore have influenced the conduction of the study, having implications for the clinical interpretation of the results.”
They did additional sensitivity analyses on several of the factors that they found that appeared may influence the OS. In the first few months of the study the death rate was actually greater in the treatment group than the control so they did analyses to see what factors may have been present to cause this. They also had to do sensitivity analyses on people that crossed over to other treatments after progression (ones outside of this trial). Additionally they used a supportive analysis using something called Restricted Mean Survival Time to show that PFS, which was not statistically significant at the Mean, did indeed separate and increase in favor of the treatment arm over time.
So, the statistical analysis has been a moving target in immune therapy trials, and all the hubbub concerning NWBO’s SAP is nothing but blather to throw off people who can’t find the time or have the skill to read through all of this. It’s confusing as hell, and it takes a lot of effort and time.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • Jul 30, 2024 8:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • BLOZF • Jul 29, 2024 9:07 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM